Preclinical and Clinical Studies of Anticancer Agent-incorporating Polymer Micelles

Overview

Journal Cancer Sci

Specialty Oncology

Date 2009 May 23

PMID 19462526

Citations 111

Authors

Yasuhiro Matsumura

Kazunori Kataoka

Affiliations

Soon will be listed here.

Abstract

The size of anticancer agent-incorporating micelles can be controlled within the diameter range of 20-100 nm to ensure that they do not penetrate normal vessel walls. With this development, it is expected that the incidence of drug-induced side-effects may be decreased owing to the reduced drug distribution in normal tissue. Micelle systems can also evade non-specific capture by the reticuloendothelial system because the outer shell of a micelle is covered with polyethylene glycol. Consequently, a polymer micelle carrier can be delivered selectively to a tumor by utilizing the enhanced permeability and retention effect. Moreover, a water-insoluble drug can be incorporated into polymer micelles. Presently, several anticancer agent-incorporating micelle carrier systems are under preclinical and clinical evaluation. Furthermore, nucleic acid-incorporating micelle carrier systems are also being developed.

Citing Articles

Long-Circulating and Brain-Targeted Liposomes Loaded with Isoliquiritigenin: Formation, Characterization, Pharmacokinetics, and Distribution.

Song W, Bai L, Xu P, Zhao Y, Zhou X, Xiong J Pharmaceutics. 2024; 16(8).

PMID: 39204320 PMC: 11359040. DOI: 10.3390/pharmaceutics16080975.

Theranostic nanoparticles for detection and treatment of pancreatic cancer.

Agarwal H, Bynum R, Saleh N, Harris D, MacCuaig W, Kim V Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024; 16(4):e1983.

PMID: 39140128 PMC: 11328968. DOI: 10.1002/wnan.1983.

Recent Advances on Pt-Based Compounds for Theranostic Applications.

Ferrari G, Lopez-Martinez I, Wanek T, Kuntner C, Montagner D Molecules. 2024; 29(15).

PMID: 39124859 PMC: 11313463. DOI: 10.3390/molecules29153453.

In Vitro Study of Tumor-Homing Peptide-Modified Magnetic Nanoparticles for Magnetic Hyperthermia.

Zhou S, Tsutsumiuchi K, Imai R, Miki Y, Kondo A, Nakagawa H Molecules. 2024; 29(11).

PMID: 38893510 PMC: 11174109. DOI: 10.3390/molecules29112632.

Modification of Polyethylene Glycol-Hydroxypropyl Methacrylate Polymeric Micelles Loaded with Curcumin for Cellular Internalization and Cytotoxicity to Wilms Tumor 1-Expressing Myeloblastic Leukemia K562 Cells.

Okonogi S, Chittasupho C, Sassa-Deepaeng T, Khumpirapang N, Anuchpreeda S Polymers (Basel). 2024; 16(7).

PMID: 38611175 PMC: 11013463. DOI: 10.3390/polym16070917.

References

Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T . Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer. 2005; 93(6):678-87. PMC: 2361620. DOI: 10.1038/sj.bjc.6602772. View

Hamaguchi T, Kato K, Yasui H, Morizane C, Ikeda M, Ueno H . A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br J Cancer. 2007; 97(2):170-6. PMC: 2360299. DOI: 10.1038/sj.bjc.6603855. View

Bodurka D, Levenback C, Wolf J, Gano J, Wharton J, Kavanagh J . Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol. 2003; 21(2):291-7. DOI: 10.1200/JCO.2003.02.091. View

Koizumi F, Kitagawa M, Negishi T, Onda T, Matsumoto S, Hamaguchi T . Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res. 2006; 66(20):10048-56. DOI: 10.1158/0008-5472.CAN-06-1605. View

Matsumura Y, Maeda H . A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986; 46(12 Pt 1):6387-92. View

Miyata K, Oba M, Kano M, Fukushima S, Vachutinsky Y, Han M . Polyplex micelles from triblock copolymers composed of tandemly aligned segments with biocompatible, endosomal escaping, and DNA-condensing functions for systemic gene delivery to pancreatic tumor tissue. Pharm Res. 2008; 25(12):2924-36. DOI: 10.1007/s11095-008-9720-2. View

Guichard S, Terret C, Hennebelle I, Lochon I, Chevreau P, Fretigny E . CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. Br J Cancer. 1999; 80(3-4):364-70. PMC: 2362335. DOI: 10.1038/sj.bjc.6690364. View

Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N . Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer. 2003; 88(3):335-41. PMC: 2747545. DOI: 10.1038/sj.bjc.6600725. View

Roth B . Chemotherapy for advanced bladder cancer. Semin Oncol. 1996; 23(5):633-44. View

10.

Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A . Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002; 346(2):85-91. DOI: 10.1056/NEJMoa003034. View

11.

Nishiyama N, Okazaki S, Cabral H, Miyamoto M, Kato Y, Sugiyama Y . Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res. 2003; 63(24):8977-83. View

12.

Pinzani V, Bressolle F, Haug I, GALTIER M, Blayac J, BALMES P . Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol. 1994; 35(1):1-9. DOI: 10.1007/BF00686277. View

13.

Bae Y, Fukushima S, Harada A, Kataoka K . Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. Angew Chem Int Ed Engl. 2003; 42(38):4640-3. DOI: 10.1002/anie.200250653. View

14.

Yokoyama M, Okano T, Sakurai Y, Ekimoto H, Shibazaki C, Kataoka K . Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. Cancer Res. 1991; 51(12):3229-36. View

15.

Kuroda J, Kuratsu J, Yasunaga M, Koga Y, Saito Y, Matsumura Y . Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma. Int J Cancer. 2009; 124(11):2505-11. DOI: 10.1002/ijc.24171. View

16.

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View

17.

Wasserheit C, Frazein A, Oratz R, Sorich J, Downey A, Hochster H . Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J Clin Oncol. 1996; 14(7):1993-9. DOI: 10.1200/JCO.1996.14.7.1993. View

18.

Sumitomo M, Koizumi F, Asano T, Horiguchi A, Ito K, Asano T . Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression. Cancer Res. 2008; 68(6):1631-5. DOI: 10.1158/0008-5472.CAN-07-6532. View

19.

Cabral H, Nishiyama N, Okazaki S, Koyama H, Kataoka K . Preparation and biological properties of dichloro(1,2-diaminocyclohexane)platinum(II) (DACHPt)-loaded polymeric micelles. J Control Release. 2004; 101(1-3):223-32. DOI: 10.1016/j.jconrel.2004.08.022. View

20.

Douillard J, Cunningham D, Roth A, Navarro M, James R, Karasek P . Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000; 355(9209):1041-7. DOI: 10.1016/s0140-6736(00)02034-1. View